Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.61 USD
Change Today +0.0044 / 0.72%
Volume 1.2M
STEM On Other Exchanges
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

stemcells inc (STEM) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/3/14 - $2.43
52 Week Low
04/24/15 - $0.54
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for STEMCELLS INC (STEM)

stemcells inc (STEM) Related Businessweek News

No Related Businessweek News Found

stemcells inc (STEM) Details

StemCells, Inc., a biopharmaceutical company, researches, develops, and commercializes cell-based therapeutics and related technologies for stem cell-based research and drug discovery and development. It engages in clinical development of its platform technology, HuCNS-SC, a purified human neural stem cells used as a potential treatment for disorders of the central nervous system. The company has completed Phase I/II clinical trial for the treatment of chronic spinal cord injury; and Phase I clinical trial for the treatment of Pelizaeus-Merzbacher disease, as well as completed enrollment and treatment in its Phase I/II clinical trial in geographic atrophy of age-related macular degeneration that cause blindness in the elderly. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California.

69 Employees
Last Reported Date: 03/13/15
Founded in 1988

stemcells inc (STEM) Top Compensated Officers

Chief Executive Officer, Director, Chief Exec...
Total Annual Compensation: $835.8K
Executive Vice President of Scientific & Stra...
Total Annual Compensation: $457.3K
Compensation as of Fiscal Year 2013.

stemcells inc (STEM) Key Developments

StemCells Seeks Acquisitions

StemCells Inc. (NasdaqCM:STEM) is seeking acquisitions. StemCells has filed a Follow-on Equity Offering, the net proceeds of which will be used for general corporate purposes, including working capital, capital expenditures and research and development, as well as acquisitions and other strategic purposes.

StemCells, Inc. Completes Enrollment of First Cohort in Phase II Pathway Study for Cervical Spinal Cord Injury

StemCells Inc. announced that it has completed transplanting the six patients comprising the first cohort of its Phase II Pathway Study. The first cohort is an open-label dose escalation arm to determine the cell dose to be used for the second cohort of the study. The second cohort of the study is a single-blind arm in 40 patients that will assess efficacy of the Company's proprietary HuCNS-SC (purified human neural stem cells) platform technology for the treatment of cervical spinal cord injury (SCI).

StemCells Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 03:40 PM

StemCells Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 03:40 PM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Martin M. McGlynn, Chief Executive Officer, Chief Executive Officer of Stemcells California Inc, President of Stemcells California Inc, Director and Member of Strategic Transactions Committee.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STEM:US $0.61 USD +0.0044

STEM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $1.16 USD -0.04
Bioheart Inc $0.0068 USD 0.00
Biorestorative Therapies Inc $0.37 USD 0.00
Cytori Therapeutics Inc $0.87 USD -0.0098
Nuo Therapeutics Inc $0.22 USD 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation STEM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 7.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 23.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STEMCELLS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at